Therapeutic formulations for the prevention, treatment and management of respiratory tract diseases and viral infections
Patent Information
- Application Number
- IN202141053381
- Authority / Receiving Office
- IN · IN
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2021-11-19
- Publication Date
- 2026-10-08
- Estimated Expiration
- 2041-11-19
AI Technical Summary
Current treatments for respiratory tract diseases and viral infections often lack effective, safe, and affordable plant-based pharmaceutical grade formulations that can prevent, treat, and manage these conditions without side effects.
A polyherbal formulation comprising specific herbal ingredients such as Withania somnifera, Aegle marmelos, Glycyrrhiza glabra, Pluchea lanceolata, Adhatoda vasica, Piper longum, Phyllanthus fraternus, Andrographis paniculata, Alstonia scholaris, Curcuma longa, Cissampelous pareira, Ocimum sanctum, and Tinospora cordifolia, processed into tablets with defined percentages, providing synergistic antimicrobial activity.
The formulation demonstrates significant antiviral activity, reducing viral load and improving respiratory symptoms with no adverse effects, as shown in in-vitro and in-vivo studies, offering a safe and cost-effective therapeutic option for respiratory tract diseases and viral infections.
Abstract
Description
FIELD OF INVENTIONThe present invention relates to the field of herbal medicinal formulations. More particularly, the present invention relates to therapeutic herbal / polyherbal formulations for the prevention, treatment and management of respiratory tract diseases and viral infections.BACKGROUNDCommon colds, cough and fever are the most prevalent of all respiratory infections and are the leading cause of patient visits to the physician, as well as work and school absenteeism. Respiratory tract immune responses are important in the prevention and pathogenesis of various respiratory tract diseases. Many of these pathogens, including mycoplasma, infect the upper respiratory tract (nasal passages) prior to dissemination to the lower respiratory tract (airways and lungs).The inventors have identified the challenge of developing newer therapeutic modalities to prevent, treat and manage respiratory tract diseases and viral infections. In particular, the inventors have developed plant-based pharmaceutical grade formulations for generating immunity against upper respiratory tract infections and viral infections which will decrease the chance of subsequent lower respiratory tract disease and viral infections.Thus, the present invention overcomes the problems of the prior art to solve a long-standing problem of providing plant-based pharmaceutical grade formulations for prevention, treatment and management of respiratory tract diseases and viral infections.OBJECTS OF THE INVENTIONAn important object of the present invention is to provide a herbal formulation for the prevention, treatment and management of respiratory tract diseases and viral infections with no side-effects.Another object of the present invention is to provide a method for preparation of said herbal formulation for the prevention, treatment and management of respiratory tract diseases and viral infections.A further object of the present invention is to provide a method of treatment comprising administration of said herbal formulation to a subject suffering from respiratory tract diseases and viral infections in a defined dosage.SUMMARY OF THE INVENTIONThe technical problem to be solved in this invention is the development of effective, inexpensive and safe plant-based pharmaceutical grade formulations for the prevention, treatment and management of respiratory tract diseases and viral infections.The problem has been solved by developing plant-based therapeutic formulations comprising one or more plant, plant part or plant extract selected from a group comprising Withania somnifera (Ashwagandha), Aegle marmelos (Bilwa), Glycyrrhiza glabra (Yastimadhu), Pluchea lanceolata (Rasna), Adhatoda vasica (Vasaka), Piper longum (Pippali), Phyllanthus fraternus (Bhumiamla), Andrographis paniculate (Bhunimba), Alstonia scholaris (Saptaparna), Curcuma longa (Haridra), Cissampelous pareira (Patha), Ocimum sanctum (Tulasi), Tinospora cordifolia (Guduci).The present invention also relates to the process for preparing a polyherbal formulation, said process comprising the steps of: (a) cleaning and drying all the herbalconstituents / ingredients; (b) grinding the dried herbal plant material of step (a) to obtain fine powder: (c) preparing the aqueous extracts from all the plants; (d) mixing the fine powders and aqueous extracts of active agents, and (e) uniformly compressing the active agents along with the excipients and preservatives to prepare tablets.The claimed formulation comprises a combination of specific herbal ingredients or plant parts in a defined percentage range, which act together in synergy to produce an enhanced effect and provides excellent antimicrobial activity associated problems. A formulation comprising all the defined components (plant parts) together and that too in specific proportions as those listed in the present specification could never have been visualized by those skilled in the art. The claimed formulation, owing to a novel combination of different plant parts in a specific percentage range exhibits surprising activity for the prevention, treatment and management of respiratory tract diseases and viral infections.Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiment.BRIEF DESCRIPTION OF THE DRAWINGSThe features of the present disclosure will become fully apparent from the following description taken in conjunction with the accompanying figures. With the understanding that the figures depict only several embodiments in accordance with the disclosure and are not to be considered limiting of its scope, the disclosure will be described further through use of the accompanying figures.Figure 1a depicts the IC50 efficacy of test material NAOQ19; Figure 1b depicts the IC50 efficacy of Remdesivir, in accordance with an embodiment of the present invention.Figure 2 depicts the improvement in lung edema, haemorrhage and congestion in NAOQ19 (NF-2) treated group as compared to the untreated group, in accordance with an embodiment of the present invention.Figure 3 depicts the less body weight reduction in NAOQ19 treated hamsters as compared to the infection control and positive control, in accordance with an embodiment of the present invention.Figure 4 depicts the log of viral load reduction in the positive control and NAOQ19 treated group compared the infection untreated group, in accordance with an embodiment of the present invention.DETAILED DESCRIPTION OF THE INVENTIONAs those in the art will appreciate, the following detailed description describes certain preferred embodiments of the invention in detail and is thus only representative and does not depict the actual scope of the invention. Before describing the present invention in detail, it is understood that the invention is not limited to the particular aspects and embodiments described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the invention defined by the appended claims.The present invention discloses formulations, methods, dosage forms and delivery systems for effective prevention, treatment and management of respiratory tract diseases and viral infections. In particular, the invention discloses therapeutic formulations comprising a number of plant components for prevention, treatment and management of respiratory tract diseases and viral infections.Before the formulations, methods, dosage forms and delivery systems of the present disclosure are described in greater detail, it is to be understood that the invention is not limited to particular embodiments and may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.DEFINITIONSEmbodiments described herein can be understood more readily by reference to the following detailed description, examples, and drawings. Elements, apparatus and methods described herein are merely illustrative of the principles of the present invention and are not limited to the specific embodiments presented in the detailed description, examples, and drawings. Numerous modifications and adaptations will be readily apparent to those of skill in the art without departing from the spirit and scope of the invention.The use of "comprise", "comprises", "comprising", "contain", "contains", "containing", "include", "includes", and "including" are not intended to be limiting. It is to be understood that both the foregoing general description and this detailed description are exemplary and explanatory only and are not restrictive.Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the methods belong. Although any nanogels, compositions or methods similar or equivalent to those described herein can also be used in the practice or testing of the embodiments of the present invention, representative illustrative methods and compositions are now described.Where a range of values is provided, it is understood that each intervening value between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within by the methods and compositions. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within by the methods and compositions, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the methods and compositions.It is appreciated that certain features of the methods, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the methods and compositions, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. It is noted that, as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely," "only" and the like in connection with the recitation of claim elements or use of a "negative" limitation.As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other embodiments without departing from the scope or spirit of the present methods. Any recited method can be carried out in the order of events recited or in any other order that is logically possible.The phrase "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.Active pharmaceutical ingredientsThe present invention relates to the preparation of a polyherbal formulation which helps to improve the condition of respiratory diseases, a preferred embodiment of said polyherbal formulation is named "NAOQ19" The claimed formulation shows improvements in terms of oxygen requirement, breathlessness, SpO2 and lung capacity. The combination of all the natural herbs makes it a completely chemical free product without any side effects.In one embodiment, at least 10, 11, 12, 13, 14, 15,16, 17, 18 or 19 plant components were used as active ingredients for the preparation of the therapeutic formulation.In another embodiment, at least 19 plant components were used for the preparation of the therapeutic formulation.In another embodiment, the active ingredients for the therapeutic formulation were plant or plant part, or extracts of plant or plant part.In another embodiment, the plant or plant part is in the form of a fine powder or extract.In another embodiment, one or more plant or plant part are selected from a group comprising Withania somnifera (Ashwagandha), Aegle marmelos (Bilwa), Glycyrrhiza glabra (Yastimadhu), Pluchea lanceolata (Rasna), Adhatoda vasica (Vasaka), Piper longum (Pippali), Phyllanthus fraternus (Bhumiamla), Andrographis paniculate (Bhunimba), Alstonia scholaris (Saptaparna), Curcuma longa (Haridra), Cissampelous pareira (Patha), Ocimum sanctum (Tulasi), Tinospora cordifolia (Guduci).In another embodiment, one or more plant extract or plant part extract used in the therapeutic formulation are selected from a group comprising Tinospora cordifolia (Guduci extract), Glycyrrhiza glabra (Yastimadhu extract), Phyllanthus fraternus (Bhumiamla extract), Adhatoda vasica (Vasaka extract), Andrographis paniculate (Bhunimba extract) and Withania somnifera (Ashwagandha extract).In another embodiment, the plant part used in the invention are selected from a group comprising, but not limited to, roots, leaf, stolen, rhizome, fruit, stem bark and the like.In one embodiment, one of the active ingredients of the therapeutic formulation is Withania somnifera (Ashwagandha).In another embodiment, the roots of Withania somnifera are used in the therapeutic formulation.In another embodiment, the roots of Withania somnifera are in the form of a fine powder or aqueous extract.In another embodiment, the quantity of Withania somnifera fine powder in the formulation is in a range from 3% to 10% w / w.In another embodiment, the quantity of Withania somnifera fine powder in the formulation is 5% w / w.In another embodiment, the quantity of Withania somnifera aqueous extract in the formulation is in a range from 3% to 10% w / w.In another embodiment, the quantity of Withania somnifera aqueous extract in the formulation is 5% w / w.In one embodiment, one of the active ingredients of the therapeutic formulation is Aegle marmelos (Bilwa).In another embodiment, the leaves of Aegle marmelos are used in the therapeutic formulation.In another embodiment, the leaves of Aegle marmelos are in the form of a fine powder.In another embodiment, the quantity of Aegle marmelos in the formulation is in a range from 3% to 10% w / w.In another embodiment, the quantity of Aegle marmelos in the formulation is 5% w / w.In one embodiment, one of the active ingredients of the therapeutic formulation is Glycyrrhiza glabra (Yastimadhu).In another embodiment, the roots or plant stolons of Glycyrrhiza glabra are used in the therapeutic formulation.In another embodiment, the roots or plant stolons of Glycyrrhiza glabra are in the form of a fine powder.In another embodiment, the roots of Glycyrrhiza glabra are in the form of an aqueous extract.In another embodiment, the quantity of Glycyrrhiza glabra fine powder in the formulation is in a range from 2% to 7% w / w.In another embodiment, the quantity of Glycyrrhiza glabra fine powder in the formulation is 3.33% w / w.In another embodiment, the quantity of Glycyrrhiza glabra aqueous extract in the formulation is in a range from 2% to 5% w / w.In another embodiment, the quantity of Glycyrrhiza glabra aqueous extract in the formulation is 2.5% w / w.In one embodiment, one of the active ingredients of the therapeutic formulation is Pluchea lanceolata (Rasna).In another embodiment, the leaves or rhizome of Pluchea lanceolata are used in the therapeutic formulation.In another embodiment, the leaves of Pluchea lanceolata are in the form of a fine powder.In another embodiment, the quantity of Pluchea lanceolata in the formulation is in a range from 3% to 10% w / w.In another embodiment, the quantity of Pluchea lanceolata in the formulation is 5% w / w.In one embodiment, one of the active ingredients of the therapeutic formulation is Adhatoda vasica (Vasaka).In another embodiment, the leaves or plantof Adhatoda vasica are used in the therapeutic formulation.In another embodiment, the leaves or plant of Adhatoda vasica are in the form of a fine powder or aqueous extract.In another embodiment, the quantity of Adhatoda vasica fine powder in the formulation is in a range from 3% to 9% w / w.In another embodiment, the quantity of Adhatoda vasica fine powder in the formulation is 4.17% w / w.In another embodiment, the quantity of Adhatoda vasica aqueous extract in the formulation is in a range from 3% to 9% w / w.In another embodiment, the quantity of Adhatoda vasica aqueous extract in the formulation is 4.17% w / w.In one embodiment, one of the active ingredients of the therapeutic formulation is Piper longum (Pippali).In another embodiment, the fruitof Piper longumare used in the therapeutic formulation.In another embodiment, the fruit of Piper longumare in the form of a fine powder.In another embodiment, the quantity of Piper longumin the formulation is in a range from 3% to 10% w / w.In another embodiment, the quantity of Piper longumin the formulation is 5% w / w.In one embodiment, one of the active ingredients of the therapeutic formulation is Phyllanthus fraternus (Bhumiamla).In another embodiment, the plant of Phyllanthus fraternus are used in the therapeutic formulation.In another embodiment, the plant of Phyllanthus fraternus are in the form of a fine powder or aqueous extract.In another embodiment, the quantity of Phyllanthus fraternus fine powder in the formulation is in a range from 4% to 12% w / w.In another embodiment, the quantity of Phyllanthus fraternus fine powder in the formulation is 5.83% w / w.In another embodiment, the quantity of Phyllanthus fraternus aqueous extract in the formulation is in a range from 3% to 10% w / w.In another embodiment, the quantity of Phyllanthus fraternus aqueous extract in the formulation is 5% w / w.In one embodiment, one of the active ingredients of the therapeutic formulation is Andrographis paniculate (Bhunimba).In another embodiment, the leaves or rhizome of Andrographis paniculate are used in the therapeutic formulation.In another embodiment, the leaves of Andrographis paniculate are in the form of a fine powder or aqueous extract.In another embodiment, the quantity of Andrographis paniculate fine powder in the formulation is in a range from 3% to 10% w / w.In another embodiment, the quantity of Andrographis paniculate fine powder in the formulation is 5% w / w.In another embodiment, the quantity of Andrographis paniculate aqueous extract in the formulation is in a range from 4% to 12% w / w.In another embodiment, the quantity of Andrographis paniculate aqueous extract in the formulation is 5.83% w / w.In one embodiment, one of the active ingredients of the therapeutic formulation is Swertia chirata (Kiratatikta).In another embodiment, thewhole plant of Swertia chirata are used in the therapeutic formulation.In another embodiment, the whole plant of Swertia chirata are in the form of a fine powder or aqueous extract.In another embodiment, the quantity of Swertia chirata fine powder in the formulation is in a range from 3% to 10% w / w.In another embodiment, the quantity of Swertia chirata fine powder in the formulation is 5% w / w.In another embodiment, the quantity of Swertia chirata aqueous extract in the formulation is in a range from 4% to 12% w / w.In another embodiment, the quantity of Swertia chirata aqueous extract in the formulation is 5.83% w / w.In one embodiment, one of the active ingredients of the therapeutic formulation is Alstonia scholaris (Saptaparna).In another embodiment, thestem barkof Alstonia scholaris are used in the therapeutic formulation.In another embodiment, the stem barkof Alstonia scholaris are in the form of a fine powder.In another embodiment, the quantity of Alstonia scholaris in the formulation is in a range from 3% to 10% w / w.In another embodiment, the quantity of Alstonia scholaris in the formulation is 5% w / w.In one embodiment, one of the active ingredients of the therapeutic formulation is Curcuma longa (Haridra).In another embodiment, the rhizome of Curcuma longa are used in the therapeutic formulation.In another embodiment, the rhizome of Curcuma longa are in the form of a fine powder.In another embodiment, the quantity of Curcuma longa in the formulation is in a range from 3% to 9% w / w.In another embodiment, the quantity of Curcuma longa in the formulation is 4.17% w / w.In one embodiment, one of the active ingredients of the therapeutic formulation is Cissampelous pareira (Patha).In another embodiment, therootof Cissampelous pareira are used in the therapeutic formulation.In another embodiment, the leaves of Cissampelous pareira are in the form of a fine powder.In another embodiment, the quantity of Cissampelous pareira in the formulation is in a range from 3% to 9% w / w.In another embodiment, the quantity of Cissampelous pareira in the formulation is 4.17% w / w.In one embodiment, one of the active ingredients of the therapeutic formulation is Ocimum sanctum (Tulasi).In another embodiment, thewhole plantof Ocimum sanctum are used in the therapeutic formulation.In another embodiment, the whole plant of Ocimum sanctum are in the form of a fine powder.In another embodiment, the quantity of Ocimum sanctum in the formulation is in a range from 2% to 7% w / w.In another embodiment, the quantity of Ocimum sanctum in the formulation is 3.33% w / w.In one embodiment, one of the active ingredients of the therapeutic formulation is Tinospora cordifolia (Guduci).In another embodiment, the stem of Tinospora cordifolia are used in the therapeutic formulation.In another embodiment, the stem of Tinospora cordifolia are in the form of a fine powder or aqueous extract.In another embodiment, the quantity of Tinospora cordifolia fine powder or aqueous extract in the formulation is in a range from 2% to 7% w / w.In another embodiment, the quantity of Tinospora cordifolia fine powder or aqueous extract in the formulation is 3.33% w / w.In another embodiment, the quantity of Tinospora cordifolia fine powder or aqueous extract in the formulation is in a range from 2% to 5% w / w.In another embodiment, the quantity of Tinospora cordifolia fine powder or aqueous extract in the formulation is 2.5% w / w.Some particular embodiments of the present invention are listed below:1. A polyherbal formulation for the prevention, treatment and management of respiratory tract diseases and viral infections, comprising:a) first component consisting of powder of Withania somnifera (Ashwagandha), Aegle marmelos (Bilwa), Glycyrrhiza glabra (Yastimadhu), Pluchea lanceolata (Rasna), Adhatoda vasica (Vasaka), Piper longum (Pippali), Phyllanthus fraternus (Bhumiamla), Andrographis paniculate (Bhunimba), Alstonia scholaris (Saptapama), Curcuma longa (Haridra), Cissampelous pareira (Patha), Ocimum sanctum (Tulasi) and Tinospora cordifolia (Guduci); and,b) a second component / plant extract consisting of Tinospora cordifolia (Guduci extract), Glycyrrhiza glabra (Yastimadhu extract), Phyllanthus fraternus (Bhumiamla extract), Adhatoda vasica (Vasaka extract), Andrographis paniculate (Bhunimba extract) and Withania somnifera (Ashwagandha extract).2. The herbal formulation as defined in embodiment 1, said formulation comprising the powder ingredients Withania somnifera (Ashwagandha) in the range of 3% to 10%, Aegle marmelos (Bilwa) in the range of 3% to 10%, Glycyrrhiza glabra (Yastimadhu) in the range of 2% to 7%, Pluchea lanceolata (Rasna) in the range of 3% to 10%, Adhatoda vasica (Vasaka) in the range of 3% to 9%, Piper longum (Pippali) in the range of 3% to 10%, Phyllanthus fraternus (Bhumiamla) in the range of 4% to 12%, Andrographis paniculate (Bhunimba) in the range of 3% to 10%, Alstonia scholaris (Saptaparna) in the range of 3% to 10%, Curcuma longa (Haridra) in the range of 3% to 9%, Cissampelous pareira (Patha) in the range of 3% to 9%, Ocimum sanctum (Tulasi) in the range of 2% to 7%, Tinospora cordifolia (Guduci) in the range of 2% to 7%.3. The herbal formulation as defined in embodiment 1, wherein the composition of the herbal formulation comprises the powder ingredients in (w / w)%, Withania somnifera (Ashwagandha) 5%, Aegle marmelos (Bilwa) 5%, Glycyrrhiza glabra (Yastimadhu) in the range of 3.33%, Pluchea lanceolata (Rasna) 5%, Adhatoda vasica (Vasaka) 4.17%, Piper longum (Pippali) 5%, Phyllanthus fraternus (Bhumiamla) 5.83%, Andrographis paniculate (Bhunimba) 5%, Alstonia scholaris (Saptaparna) 5%, Curcuma longa (Haridra) 4.17%, Cissampelous pareira (Patha) 4.17%, Ocimum sanctum (Tulasi) 3.33%, Tinospora cordifolia (Guduci) 3.33%.4. The herbal formulation as defined in embodiment 1, wherein the composition of the herbal formulation comprises the plant part extract ingredients in the range of 2% to 5% Tinospora cordifolia (Guduci extract), 2% to 5% Glycyrrhiza glabra (Yastimadhu extract), 3% to 10% Phyllanthus fraternus (Bhumiamla extract), 3% to 9% Adhatoda vasica (Vasaka extract), 4% to 12% Andrographis paniculate (Bhunimba extract) and 3% to 10% Withania somnifera (Ashwagandha extract).5. The herbal formulation as defined in embodiment 1, wherein the composition of the herbal formulation comprises the plant part extract ingredients in (w / w)% Tinospora cordifolia (Guduci extract) 2.5%, Glycyrrhiza glabra (Yastimadhu extract) 2.5%, Phyllanthus fraternus (Bhumiamla extract) 5%, Adhatoda vasica (Vasaka extract) 4.17%, Andrographis paniculate (Bhunimba extract) 5.83% and Withania somnifera (Ashwagandha extract) 5%.6. The herbal formulation as defined in embodiment 1, further containing optionally at least one component selected from pharmaceutically acceptable carrier, excipient, and preservative.7. The herbal formulation as defined in embodiment 1, wherein the herbal formulation comprises plant parts selected from the group comprising of fruits, stem barks, leaves, roots, stolen, whole plants and rhizomes.8. The herbal formulation as defined in embodiment 1, wherein the formulation can be administered in the form of tablets, capsules, pills, powders, granules, aqueous and nonaqueous oral solutions and suspensions, creams, hard candies, lozenges, troches, sprays, salves, suppositories, gels, pastes, ointments, jellies, lotions, injectable solutions, elixirs, syrups, and parenteral solutions that is suitable for direct consumption.9. The herbal formulation as defined in embodiment 6, wherein the excipients added in the formulation are selected from the group of starch, crospovidone, croscarmellose sodium, microcrystalline cellulose powder and silicon dioxide (Aerosil).10. The herbal formulation as defined in embodiment 6, wherein the preservatives added in the formulation are one or more of sodium benzoate and potassium sorbate.11. A process for preparing a herbal formulation, said method comprising the steps of:a) Collecting one or more plant parts selected from flowers, fruits, leaves, seeds, roots, kernels or whole plant, wherein the plant parts are selected from Withania somnifera (Ashwagandha), Aegle marmelos (Bilwa), Glycyrrhiza glabra (Yastimadhu), Pluchea lanceolata (Rasna), Adhatoda vasica (Vasaka), Piper longum (Pippali), Phyllanthus fraternus (Bhumiamla), Andrographis paniculate (Bhunimba), Alstonia scholaris (Saptaparna), Curcuma longa (Haridra), Cissampelous pareira (Patha), Ocimum sanctum (Tulasi) and Tinospora cordifolia (Guduci);b) washing the plant parts obtained in step a) to remove unwanted contaminants and drying the same at room temperature;c) grinding the following dried herbal plant material of step (a) to obtain fine powder:i. Withania somnifera (Ashwagandha) 5%,ii. Aegle marmelos (Bilwa) 5%,iii. Glycyrrhiza glabra (Yastimadhu) 3.33%,iv. Pluchea lanceolata (Rasna) 5%,v. Adhatoda vasica (Vasaka) 4.17%,vi. Piper longum (Pippali) 5%,vii. Phyllanthus fraternus (Bhumiamla) 5.83%,viii. Andrographis paniculate (Bhunimba) 5%,ix. Alstonia scholaris (Saptaparna) 5%,x. Curcuma longa (Haridra) 4.17%,xi. Cissampelous pareira (Patha) 4.17%,xii. Ocimum sanctum (Tulasi) 3.33%, andxiii. Tinospora cordifolia (Guduci) 3.33%,d) preparing the aqueous extracts from the following plants:i. Tinospora cordifolia (Guduci extract) 2.5%,ii. Glycyrrhiza glabra (Yastimadhu extract) 2.5%,iii. Phyllanthus fraternus (Bhumiamla extract) 5%,iv. Adhatoda vasica (Vasaka extract) 4.17%,v. Andrographis paniculate (Bhunimba extract) 5.83% andvi. Withania somnifera (Ashwagandha extract) 5%.e) mixing the fine powders and aqueous extracts of active agents,f) uniformly compressing the active agents along with the excipients and preservatives to prepare tablets.ExcipientsThe formulations of the present invention may further comprise pharmaceutically acceptable carriers, excipients, and preservatives. The carriers and excipients include but are not limited to, solid diluents or fillers, excipients, sterile aqueous media and various non-toxic organic solvents.In one embodiment, the excipients used in the therapeutic formulation are selected from a group comprising one or more of starch, crospovidone, croscarmellose sodium, microcrystalline cellulose powder and silicon dioxide (Aerosil).In one embodiment, the quantity of starch (Indian Pharmacopeia Vol-3; Pages 3269-3270) in the formulation is in a range from6% to 17% w / w.In another embodiment, the quantity of starch in the formulation is 8.33% w / w.In one embodiment, the quantity of crospovidone (Indian Pharmacopeia Vol-2; Pages 14691470) in the formulation is in a range from 1% to 4% w / w.In another embodiment, the quantity of crospovidone in the formulation is 2% w / w.In one embodiment, the quantity of croscarmellose sodium (Indian Pharmacopeia Vol-2; Pages 1470-1471) in the formulation is in a range from1% to 4% w / w.In another embodiment, the quantity of croscarmellose sodium in the formulation is 1.66% w / w.In one embodiment, the quantity of microcrystalline cellulose powder (Indian Pharmacopeia Vol-2; Pages 2229-2230) in the formulation is in a range from2% to 7% w / w.In another embodiment, the quantity of microcrystalline cellulose powder in the formulation is 3.5% w / w.In one embodiment, the quantity of silicon dioxide (Indian Pharmacopeia Vol-1; Page 811) in the formulation is in a range from1% to 2% w / w.In another embodiment, the quantity of silicon dioxide in the formulation is 0.83% w / w. PreservativesThe formulations of the present invention may further comprise a pharmaceutically acceptable preservative.In one embodiment, the preservatives used in the therapeutic formulation are selected from a group comprising one or more of sodium benzoate and potassium sorbate.In one embodiment, the quantity of sodium benzoate (Indian Pharmacopeia Vol-3; Pages 2739-2739) in the formulation is in a range from 0.1% to 1% w / w.In one embodiment, the quantity of potassium sorbate (Indian Pharmacopeia Vol-3; Pages 2527-2528) in the formulation is in a range from0.1% to 1% w / w. Preparation of tabletIn one embodiment, the tablets were prepared by mixing the fine powders and aqueous extracts of one or more active agents, and uniformly compressing the active agents along with the excipients and preservatives to prepare tablets.In one embodiment the plant-based therapeutic formulation comprises one or more plant, plant part or plant extract selected from a group comprising Withania somnifera (Ashwagandha), Aegle marmelos (Bilwa), Glycyrrhiza glabra (Yastimadhu), Pluchea lanceolata (Rasna), Adhatoda vasica (Vasaka), Piper longum (Pippali), Phyllanthus fraternus (Bhumiamla), Andrographis paniculate (Bhunimba), Alstonia scholaris (Saptaparna), Curcuma longa (Haridra), Cissampelous pareira (Patha), Ocimum sanctum (Tulasi), Tinospora cordifolia (Guduci) in a defined percentage range.In an embodiment of the herbal formulation the components of the present invention are such that the powder ingredients are in the range of 3% to 10% Withania somnifera (Ashwagandha), Aegle marmelos (Bilwa) in the range of 3% to 10%, Glycyrrhiza glabra (Yastimadhu) in the range of 2% to 7%, Pluchea lanceolata (Rasna) in the range of 3% to 10%, Adhatoda vasica (Vasaka) in the range of 3% to 9%, Piper longum (Pippali) in the range of 3% to 10%, Phyllanthus fraternus (Bhumiamla) in the range of 4% to 12%, Andrographis paniculate (Bhunimba) in the range of 3% to 10%, Alstonia scholaris (Saptaparna) in the range of 3% to 10%, Curcuma longa (Haridra) in the range of 3% to 9%, Cissampelous pareira (Patha) in the range of 3% to 9%, Ocimum sanctum (Tulasi) in the range of 2% to 7%, Tinospora cordifolia (Guduci) in the range of 2% to 7%.Dosage formsThe therapeutic formulations of the present invention may be manufactured in one or more pharmaceutically acceptable dosage forms.Dosage unit forms or pharmaceutical formulations include tablets, capsules, pills, powders, granules, aqueous and non-aqueous oral solutions and suspensions, creams, hard candies, lozenges, troches, sprays, salves, suppositories, gels, pastes, ointments, jellies, lotions, injectable solutions, elixirs, syrups, and parenteral solutions packaged in containers adapted for subdivision into individual doses.In one embodiment, the dosage form is a tablet.In another embodiment, the dosage unit forms may be packed in units of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200 or 500.The formulations as disclosed herein can be used as a medicament or as a component in a pharmaceutical composition. Pharmaceutical compositions include sprays, suppositories, pastes, ointments, jellies, lotions, injectable solutions, and parenteral solutions packaged in containers adapted for subdivision into individual doses.Parenteral formulations include pharmaceutically acceptable aqueous or non-aqueous solutions, dispersion, emulsions, suspensions for the preparation thereof. Non-limiting examples of carriers include water, ethanol, polyols (such as propylene glycol, polyethylene glycol), vegetable oils, and injectable organic esters such as ethyl oleate. Fluidity can be maintained using a coating such as lecithin, a surfactant, or maintaining appropriate particle size. Exemplary parenteral administration forms include solutions or suspensions of the compounds of the invention in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.Methods of treatmentIn another embodiment, the invention provides a method for prevention, treatment and management of respiratory tract diseases and viral infections by administration of a therapeutically effective amount of formulation as may be need on a case-to-case basis.Respiratory tract diseases and viral infections may be indicated by symptoms such as fever and cough along with one or more one or more signs or symptoms characterizing the disease, as well known to a medical practitioner.In reference to the treatment, prevention or management of respiratory tract diseases and viral infections, an effective amount refers to that amount which has the effect of reducing or inhibiting (that is, slowing to some extent, preferably stopping) one or more signs or symptoms characterizing one or more respiratory tract diseases and viral infections.In certain embodiments, formulation may be administered in one or more dosage forms.Those skilled in the art will be able to determine, according to known methods, the appropriate amount, dose or dosage of the formulation for administration to a subject taking into account factors such as age, weight, general health, the compositions administered, the route of administration, the nature and advancement of diseases requiring treatment, and the presence of other medications.The formulation may be administered together or independently of one another by any route known to a person skilled in the art, such as by oral, intravenous, topical, intraperitoneal or nasal route.Preferable mode for administration of the formulations of the present invention is oral administration.In certain embodiments, the formulations are administered at a pre-determined daily dosage. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation.In one embodiment, the daily dosage is 2-3 tablets twice or thrice a day after food.In another embodiment, the daily dosage is prescribed by a physician or medical practitioner.The practice of the method of this invention may be accomplished through various administration or dosing regimens. The formulations of the present invention can be administered intermittently, concurrently, or sequentially with other prescribed pharmaceutical compositions.Repetition of the administration or dosing regimens may be conducted as necessary to achieve levels of treatment.While the foregoing describes various embodiments of the disclosure, other and further embodiments of the disclosure may be devised without departing from the basic scope thereof. The scope of the invention is determined by the claims that follow. The invention is not limited to the described embodiments, versions or examples, which are included to enable a person having ordinary skill in the art to make and use the invention when combined with information and knowledge available to the person having ordinary skill in the art.EXAMPLESThe present invention is further explained in the form of following examples. The following examples particularly describe the manner in which the invention is to be performed. However, it is to be understood that the following examples are merely illustrative and are not to be taken as limitations upon the scope of the invention.Example 1: Preparation of polyherbalformulationRequired plant parts such as flowers, fruits, leaves, seeds, roots, whole plant were collected, selected from Withania somnifera (Ashwagandha), Aegle marmelos (Bilwa), Glycyrrhiza glabra (Yastimadhu), Pluchea lanceolata (Rasna), Adhatoda vasica (Vasaka), Piper longum (Pippali), Phyllanthus fraternus (Bhumiamla), Andrographis paniculate (Bhunimba), Alstonia scholaris (Saptaparna), Curcuma longa (Haridra), Cissampelous pareira (Patha), Ocimum sanctum (Tulasi) and Tinospora cordifolia (Guduci). The plant parts were cleaned thoroughly by washing to remove unwanted contaminants and dried at room temperature.The dried herbal plant material was ground to obtain a fine powder. The fine powder and aqueous extracts obtained from the herbal ingredients are mixed by uniform compressing along with the excipients and preservatives to prepare tablets.Table 1 lists an exemplary polyherbal formulation in accordance with the present disclosure, wherein the ingredients are listed as weight percentage with respective plant parts used for formulation.Table 1: Exemplary polyherbal formulation Each 500 mg of the active agent mixture contains:The following excipients and preservatives were added to the mixture of active agents:Table:The exemplary polyherbal formulation NAOQ19 contains 19 ingredients made with 13 herbs, comprisings: (a) the first component / part and (b) second component. The first component / part consists of a powder of (w / w)%, Withania somnifera (Ashwagandha) 5%, Aegle marmelos (Bilwa) 5%, Glycyrrhiza glabra (Yastimadhu) in the range of 3.33%, Pluchea lanceolata (Rasna) 5%, Adhatoda vasica (Vasaka) 4.17%, Piper longum (Pippali) 5%, Phyllanthus fraternus (Bhumiamla) 5.83%, Andrographis paniculate (Bhunimba) 5%, Alstonia scholaris (Saptaparna) 5%, Curcuma longa (Haridra) 4.17%, Cissampelous pareira (Patha) 4.17%, Ocimum sanctum (Tulasi) 3.33%, Tinospora cordifolia (Guduci) 3.33%. The second component consists of aqueous extracts of Tinospora cordifolia (Guduci extract) 2.5%, Glycyrrhiza glabra (Yastimadhu extract) 2.5%, Phyllanthus fraternus (Bhumiamla extract) 5%, Adhatoda vasica (Vasaka extract) 4.17%, Andrographis paniculate (Bhunimba extract) 5.83% and Withania somnifera (Ashwagandha extract) 5%.The therapeutic herbal formulations obtained further may be manufactured in one or more pharmaceutically acceptable dosage forms such as tablets.Example 2: In-vitro evaluationThe present study evaluates the antiviral efficacy of a novel Ayurvedic polyherbal formulation, NAOQ19, composed of a 13 well known herbs, in a cell-based setting.Vero E6 (CL1008), the African green monkey kidney epithelial cell line was obtained from Elabscience Biotechnology Inc. (Cat no. EP-CL-0491) and cultured in DMEM supplemented with 10% FBS and antibiotic antimycotic solutions at 37 °C in a humidified CO2 (5%) incubator.Briefly, Vero E6 (CL1008), the African green monkey kidney epithelial cell, were infected with SARS-CoV-2 virus (isolate USA-WA1 / 2020) in a 96 well-plate. NAOQ19 test material was diluted at different concentration: 0.05 mg / ml, 0.1 mg / ml, 0.2 mg / ml, 0.3 mg / ml, 0.4 10 mg / ml, 0.5 mg / ml, 0.6 mg / ml, 0.7 mg / ml, 0.8 mg / ml and 0.9 mg / ml. These different concentrations of NAOQ19 were added to infected cells respectively and incubated for 3 days in 5% CO2 incubator. Remdesivir was used as a positive control. The cells were finally fixed with formaldehyde, stained with crystal violet and plaques were visualized. The number of plaques were counted to determine the PFU (plaque forming units) / ml.Results:Plaque Assay Data table (Table 2) represents the various concentrations of test material NAOQ19, positive control remdesivir and corresponding plaque forming units at different concentrations. The test was run in duplicates and the average plaque forming units were calculated.Table 2: Viral load reduction among different concentrations of NAOQ19NAOQ19 was found to exhibit antiviral activity against SARS-CoV-2. The highest antiviral activity noted was 100% viral load reduction at a concentration of 0.9 mg / ml (Table 2). At this concentration, NAOQ19 was found to nullify the virus completely. The IC50 was calculated by considering the top value of 100 and baseline value of 0 and was found to be 0.2 mg / mL (Fig. 1a).The IC50 value of positive control (Remdesivir) was calculated by considering the top value of 100 and baseline value 0 (Table 2). The reported IC-50 was 1.3 pM (Fig. 1b).The virus only and cell only controls ensured the efficacy of viral isolates, cell lines used and the test procedure. By providing respective controls, it was ensured that the antiviral effects in test material arm were caused only due to the antiviral efficacy of NAOQ19 and not due to any toxicity.The results of the present study demonstrated excellent viral load reduction using NAOQ19 in Vero E6 cell lines infected with SARS-CoV-2 virus. The study results show complete elimination of the virus (100% antiviral efficacy) at a concentration of 0.9 mg / ml. The IC50 was found to be 0.2 mg / mL. The results highlight NAOQ19's potential efficacy against COVID-19. The present study along with the in vivo preclinical studies and clinical trial results propose a beneficial therapeutic for the prevention, treatment and management of respiratory tract diseases and viral infections such as SARS CoV-2.Example 3: Efficacy of claimed therapeutic herbal formulations:The following non-limiting examples shall serve to describe the efficacy of the invention.Example 3a: In-vivo efficacy and safety of the herbal formulation in Syrian golden hamster modelThe purpose of this study is to evaluate the in vivo antimicrobial efficacy of the exemplary herbal formulation NAOQ19 of the present invention against the COVID-19 infected Syrian golden hamsters (Mesocricetus auratus) in experimental laboratory. All the herbs & herbal extracts which constituted NAOQ19 were subjected for quality control analysis and NOQ 19 was supplied in the powdered form and stored at 4oC until further use.A total of 19 female Syrian hamsters were infected with the SARS-CoV-2 virus cell culture through intranasal route. 4 out of 19 animals were mock controls, 5 were infection controls, 4 were treated with remdesivir and acted as positive controls and remaining 6 were treated with NAOQ19 powder (dosage -1000mg / kg). The hamsters were observed for 3 days post virus inoculation to note body weight reduction and adverse events followed by sacrifice on day 4. Thereafter, the lung pathology and viral load was studied in each hamster.Results:Results of this study showed a significant reduction of 78.2% in the lung viral load for the NAOQ19 arm, as compared to the infection control. Gross examination of the lung pathology of the animals treated with NAOQ19 suggested an improvement in edema and congestion compared to the infection control. Also, no adverse events or toxicity were observed in NAOQ19 hamster group.The results show that therapeutic use of intraperitoneal instillation of the polyherbal formulation prevents SARS-CoV-2 viral load and associated gross clinical parameters. Gross pathological observations demonstrated normal hamster lungs in the non-infected group. The infected untreated group demonstrated severe edema and inflammation in all lobes. As shown in Figure 2, the infected untreated group also had diffused multi-focal haemorrhage and congestion. The NAOQ19 (NF-2) group showed improvement in lung edema, haemorrhage and congestion as compared to the untreated group.The hamsters in uninfected mock control demonstrated an increase in their body weights during the study period. The infected but untreated hamsters showed a reduction in the body weight. NAOQ19 treated hamsters showed less body weight reduction when compared to the infection control and positive control as shown in Figure 3.The log of Viral load reduction in the positive control and NAOQ19 group compared the infection untreated group, the reduction of viral load in NAOQ19 group was 78.2% as shown in Figure 4. The test item NF-2 (NAOQ19) showed significant antiviral activity at 1000mg / kg BID dosing in comparison to the untreated control group as represented in Table 2 below:Table 2:This pre-clinical study focuses on the efficacy of the formulation in an animal model. As noted in the untreated infected hamsters, intranasal application of SARS-CoV-2 produces severe haemorrhage, congestion, edema and lung pathologies. However, the pathological severity was reduced among the NAOQ19 treated group. Also, none of the hamsters in NAOQ19 treatment group reported any toxicity or adverse events after the NAOQ19 inoculation. This demonstrated the safety of the NAOQ19 among the hamster model.Example 3b: Efficacy of the herbal formulation in symptomatic management of mild COVID-19 casesIn this experiment, a double blinded, randomized placebo-controlled clinical trial was performed in 50 patients with confirmed symptomatic or asymptomatic case of COVID-19. A total of 50 participants were enrolled in this study, 25 patients in the NAOQ19 arm and 25 patients in the placebo arm. Participants enrolled in the NAOQ19 arm were given the NAOQ19 tablets. The dosage for NAOQ19 arm was 2 tablets (500 mg each) thrice a day after food for 10 days. The placebo control group was provided the placebo tablets made of starch. They were packed in bottles identical to the NAOQ19 bottles by Sri Sri Tattva. The dosage for placebo arm was also 2 tablets (500 mg each) thrice a day after food for 10 days. In addition to receiving NAOQ19 or placebo, both groups received the standard treatment according to the government guidelines. The standard treatment included Azithromycin (500mg, once a day for 5 days) or Doxycycline (100mg, twice a day for 5 days), Levocetrizine (5mg once a day for 5 days), Vitamin C (10 days), Zinc (10 days) and Paracetamol (500mg, as required).Those who did not adhere to the protocol or could not comply were excluded from the data analysis. No significant difference was found in the age and gender distribution or comorbidities between the two groups. The duration between the onset of symptoms, positive COVID-19 test and the enrolment in NAOQ19 or control arm group was also similar. The study duration was around 3 months, and the intervention period for an individual patient was 10 days. Both the groups were predominantly male.Table 3 lists the demographic characteristics of the study population.Table 3: Demographic Characteristics of the study populationTable 3 shows no significant difference in the age and gender distribution between the two groups. The duration between the onset of symptoms, positive COVID-19 test and the enrolment in NAOQ19 or placebo arm was also similar.Primary Outcome - % population with RT-PCR Negative test 19 out of the 25 patients (76%) in the NAOQ19 arm turned RT-PCR negative after 5 days of treatment (Table 4). By Day10 all patients in both arms were RT-PCR negative.Table 4: Percentage of Population with RT-PCR negative test at Day 05Table 4 shows that NF2 arm had a 76% increase in patients who turned RT-PCR negative on Day 5, while the placebo arm showed no improvement. Patients in the NF2 arm showed an early and strong recovery from COVID-19.The secondary outcomes of this study included subjective parameter assessments of sore throat, cough, runny nose, shortness of breath, joint pain, fatigue, malaise, headache, loss of smell and loss of taste in both groups on Day 5 and Day 10. Significant improvements in the symptomatic clinical features of COVID-19 were observed in the NAOQ19 arm in comparison to the placebo arm. On Day 5, the population in the NAOQ19 arm showed a complete recovery from sputum formation, sore throat, headache, joint pains, fatigue, runny nose, loss of smell, loss of taste and fever. By Day 10, 90-100% of the population in the NAOQ19 arm showed a complete recovery from all symptoms, unlike the control arm.The results of this experiment showed that NAOQ19 facilitated a complete recovery from all clinical features of COVID-19 faster, when compared to the control. No adverse events or side effects were observed during the entire study duration. This study is significant in observing the changes in viral load and clinical symptoms for the COVID-19 patients.Example 3c: Efficacy in improvement of mild to moderate category of COVID-19 infected patientsA multicentric, randomized, placebo control design was adopted for the experiment. A total of 76 patients with positive COVID-19 RT-PCR test was enrolled in the study: 39 in the NAOQ19 arm and 37 in the placebo arm. Patients were randomized and blinded to their respective intervention, which was provided along with the standard of care treatment. The standard of care treatment was administered as per the guidelines provided by the Ministry of Health and Family welfare, Government of India, during the second wave of COVID-19.Rate of recovery assessment was done on Day 3, 5 and 7 via RT-PCR test to measure the rate of recovery. Blood markers were analysed on Day 0 and Day 7.Results:The results of this study demonstrated a significant early recovery in the patients who took the NAOQ19 formulation. Patients who received NAOQ19 with the standard care of treatment showed clinical improvement in terms of oxygen requirement, breathlessness and SpO2. Moreover, no side effects were observed with the use of NAOQ19.Table 5: Percentage rate of recovery among NAOQ19 arm and Placebo arm as measured by RT-PCR negative populationThe RT-PCR analysis of patients in the NAOQ19 arm on day 3 showed a higher percentage of recovered population (44%), compared to the placebo arm (34%). The trend continued on day 5 and day 7, with a slightly higher percentage of population recovering in the NAOQ19 arm compared to the Placebo arm. However, the subgroup analysis of patients with moderate infection (requiring hospitalization), demonstrated a significant rate of recovery at Day 3 in the NAOQ19 arm. 75% of the patients recovered at day 3 itself in the NAOQ19 arm, while a slow and gradual improvement in the placebo arm was noticed over the course of the week. A key observation of this study was the improvement in oxygen levels and reduction in breathlessness among patients with COVID-19, when treated with NAOQ19.Example 3d: Efficacy on the rate of recovery and clinical improvement among moderate-severe COVID-19 infected patientsThis study investigates the efficacy of NAOQ19 on the rate of recovery and clinical improvement among moderate-severe COVID-19 infected patients who were not on a ventilator or in intensive care unit. A placebo controlled randomized study design, with 1:1 ratio between the intervention and placebo arms was adopted. The participants were provided their respective intervention along with the standard of care treatment. A follow up was conducted on Day 7 and Day 10 to assess the rate of recovery and clinical improvement. Rate of recovery was the primary outcome measured and was determined by a negative result on the RT-PCR test. The secondary outcomes included clinical improvement among patients and were measured using blood biomarkers.Table 6: Percentage Population with RT-PCR Negative test at Day 7 and Day 10Table 6 demonstrates the inter and intra group analysis of COVID-19 recovery and viral load reduction as measured by RT-PCR negativity rate at different time points. Among the NAOQ19 arm, 23% (n=5) of the patients were negative on Day 7 while only 11% (n=2) patients were negative in the placebo group. However, on Day 10, the number of patients who were negative in the intervention arm was 37% (n=8), and 50% (n=9) in the placebo arm. At both the time points the difference was not statistically significant between the groups. However, when the patients were grouped by severity of disease (moderate and severe), and analysed thereafter, a significant increase in the number of patients turning RTPCR negative on day 7 was observed among both moderate and severe patients in the NAOQ19 arm. Among the severe patients, the NAOQ19 arm demonstrated an early recovery.Results:The NAOQ19 arm had a higher percentage of population who turned RT-PCR negative on Day 7 (23%) when compared to the placebo arm (11%). Further subgroup analysis demonstrated that for both moderate and severe patients, there were a greater percentage of population who were RT-PCR negative in the NAOQ19 arm compared to the placebo arm at Day 7: (NOQ-19: 22.22%, Placebo: 14.29% for moderate patients), (NAOQ19: 23.08% Placebo: 0% for severe patients). By Day 10, both populations depicted an almost similar percentage of the population who were RT- PCR negative. Both the groups demonstrated an improvement in blood biomarkers, although the improvement was greater in the NAOQ19 arm. None of the patients in the intervention arm reported any adverse events. The results of this study indicates that NAOQ19 along with standard of care treatment can be considered as an effective therapy for COVID-19 and aid early recovery from the disease.Example 3e: Efficacy on the recovery of mild, RT-PCR positive COVID-19 patientsThis was a prospective, double blind, randomized control trial that included 92 patients with a RT-PCR positive mild case of COVID-19. The patients were enrolled from rural areas of Karnataka, a state in India. The patients were randomized between the NF2 and placebo arms, in a 1:1 ratio, and were provided their respective intervention, along with the standard of care treatment (SOC). The trial took place at the Community Care Center, Konnanuru, Hassan, Karnataka. The study duration was around 2 months and the follow-up period for an individual patient was 14 days. RT-PCR analysis was done at baseline, Day 3, 7 and 10. Blood markers to track inflammation were assessed at baseline, Day 3 and 7.Table-7 demonstrates a significantly higher percentage of population was found to be RT35 PCR negative in the NAOQ19 arm, at all assessment time points. The NOQ 19 arm showed a significant increase in negative patients in 3 days (19%, pvalue 0.012) while the placebo arm had no improvement on Day 3. On the 7th day, 41% of patients in the NAOQ19 arm had a negative RT-PCR compared to 18% of patients in the placebo arm. By Day 10, 73% of patients in the NAOQ19 arm had turned negative compared to 44% in the placebo arm (p value 0.035). The intra group p values were found to be significant among both the groups. Overall, the NAOQ19 arm showed a faster recovery.Table 7: Percentage of population turning of RT-PCR negativityResults:A statistically significant difference was observed between the two groups with regards to the percentage of population who turned RT-PCR negative on Day 3 and Day 10. On all three assessment time points (Day 3, 7 and 10), the NF2+SOC arm showed a greater percentage of population who were RT-PCR negative compared to the placebo+SOC arm: Day 3 (NF2 - 19%, Placebo - 0%) ; Day 7 (NF2- 41%, Placebo - 19%) ; Day 10 (NF2-73%, Placebo 44%).No significant changes were observed in blood markers for both the groups. No adverse events or side effects in the population taking NAOQ19 during the study duration.Example 3f: Rate of Recovery and Symptomatic efficacy in the management of COVID-19 A single centre, open label study design was adopted for this feasibility study. 161 home isolated, RT-PCR positive COVID-19 patients were enrolled. The enrolled participants were provided the intervention, 2 tablets of NAOQ19, thrice daily along with the standard of care treatment. Follow up COVID-19 RT- PCR tests were conducted on Day 5, Day 10 and Day 14, or until the patient turned negative. The time required for testing negative on the RT-PCR test or becoming asymptomatic was noted.Table 8 represents the RT-PCR test results. The evaluation of test results demonstrated that 115 (74%) subjects turned RT-PCR Negative on Day 5 after taking NAOQ19 along with the standard of care treatment, 23 (14%) subjects turned RT-PCR Negative on Day 7 after taking NAOQ19 along with the standard care. 16 (10%) subjects turned RT-PCR Negative on Day 10 after taking NAOQ19 along with the standard care. 1 subject turned RT-PCR Negative on Day 14 after taking NAOQ19 along with the standard care. None of the patients in the study reported any side effects. No adverse events were reported.Table 8: RT-PCR test resultsResults:A subjective analysis demonstrated that 74% and 98% of patients turned RT-PCR negative within 5 and 10 days of taking NAOQ19, respectively in addition to the standard of care treatment of Vitamin C, Zinc and antipyretic (as necessary). None of the participants reported any adverse or side effects to the medication.Example 3g: Oral toxicity effectsThis experiment was carried out to determine the toxicity of the polyherbal formulation of the present invention by an oral administration in mice. It was assessed for 14 days toxicity by employing 425-OECD guidelines. The dose (5000 mg / kg per mice, orally-one time) was given to mice and observed for 14 days, for general appearance, cage side behavior including increased or decreasing motor activity, convulsions, straub's reaction, catatonia, muscle spasm, spasticity, hyperesthesia, muscle relaxation, anesthesia, arching and rolling, lacrimation, salivation, diarrheal, writhing movement, mode of respiration and changes in skin colour etc., with mean body weight and any mortality finding at the end of 14 days.Results:Table 9 depicts the physical and gross behavioural changes in Wistar albino mice at 2, 4 and 24 h after dosing of NF2.Table 10 demonstrates the physical and gross behavioural changes in Wistar albino mice at 7 th day after dosing of NF2 drug and there after daily once for mortality.Table 11 demonstrates the physical and gross behavioural changes in Wistar albino mice at 14 th day after dosing of NF2 drug and there after daily once for mortality.Table 12 shows the 7th and 14th day data revealed that no significant changes in body weight in NF2 treated groups compared to control group.Table 12: Effect of NF2 on body weight of mice (14 days toxicity)Values represent the mean ± SEM (n = 3); ns= non-significantAll the animals belonging to the treated group survived throughout the 14 days observation period after dosing. The formulation did not produce any mortality at 5000 mg / kg per oral dose. It also did not produce any observable toxic effect, no significant changes in mean body weight. Based on the observation made and recorded for 14 days study, it can be concluded that the formulation has no toxic potential even at the dose of 5000 mg / kg in mice per oral.The embodiments illustrated and discussed in the specification are intended only as exemplary and the many other feasible embodiments within the scope of the invention will be readily understood and appreciated. Nothing in the specification should be constructed as limiting scope of present Invention. Many changes may be made to produce a highly effective polyherbal formulation for the prevention, treatment and management of respiratory tract diseases and viral infections with no side-effects, without departing from the present invention.ADVANTAGES OF THE INVENTIONThe claimed therapeutic formulations represent an advancement over the existing methods for effective management of respiratory tract diseases and viral infections. The advances are characterized by the following features:(a) Efficacy: The formulations of the present invention are highly effective for the prevention, treatment and management of respiratory tract diseases and viral infections.(b) Affordable: The formulations developed are highly inexpensive, safe and can be afforded even by people in developing and least-developed nations.(c) Reproducible with no batch-to-batch variation: The formulations of the present invention are of pharmaceutical grade and do not exhibit variability from batch to batch.(d) High shelf life: The formulations of the present invention have a high shelf life and can be made available as ready-to-use formulations.(e) No side effects: The formulations of the present invention have no side or off target effects.The developed formulations have potential to evolve as commercial product against the prevention, treatment and management of respiratory tract diseases and viral infections.
Claims
1. A polyherbal formulation for the prevention, treatment and management of respiratory tract diseases and viral infections, comprising: a) first component consisting of powder of Withania somnifera (Ashwagandha), Aegle marmelos (Bilwa), Glycyrrhiza glabra (Yastimadhu), Pluchea lanceolata (Rasna), Adhatoda vasica (Vasaka), Piper longum (Pippali), Phyllanthus fraternus (Bhumiamla), Andrographis paniculate (Bhunimba), Alstonia scholaris (Saptaparna), Curcuma longa (Haridra), Cissampelous pareira (Patha), Ocimum sanctum (Tulasi) and Tinospora cordifolia (Guduci); and, b) a second component / plant extract consisting of Tinospora cordifolia (Guduci extract), Glycyrrhiza glabra (Yastimadhu extract), Phyllanthus fraternus (Bhumiamla extract), Adhatoda vasica (Vasaka extract), Andrographis paniculate (Bhunimba extract) and Withania somnifera (Ashwagandha extract).
2. The herbal formulation as claimed in claim 1, said formulation comprising the powder ingredients Withania somnifera (Ashwagandha) in the range of 3% to 10%, Aegle marmelos (Bilwa) in the range of 3% to 10%, Glycyrrhiza glabra (Yastimadhu) in the range of 2% to 7%, Pluchea lanceolata (Rasna) in the range of 3% to 10%, Adhatoda vasica (Vasaka) in the range of 3% to 9%, Piper longum (Pippali) in the range of 3% to 10%, Phyllanthus fraternus (Bhumiamla) in the range of 4% to 12%, Andrographis paniculate (Bhunimba) in the range of 3% to 10%, Alstonia scholaris (Saptaparna) in the range of 3% to 10%, Curcuma longa (Haridra) in the range of 3% to 9%, Cissampelous pareira (Patha) in the range of 3% to 9%, Ocimum sanctum (Tulasi) in the range of 2% to 7%, Tinospora cordifolia (Guduci) in the range of 2% to 7%.
3. The herbal formulation as claimed in claim 1, wherein the composition of the herbal formulation comprises the powder ingredients in (w / w)%, Withania somnifera (Ashwagandha) 5%, Aegle marmelos (Bilwa) 5%, Glycyrrhiza glabra (Yastimadhu) in the range of 3.33%, Pluchea lanceolata (Rasna) 5%, Adhatoda vasica (Vasaka) 4.17%, Piper longum (Pippali) 5%, Phyllanthus fraternus (Bhumiamla) 5.83%, Andrographis paniculate (Bhunimba) 5%, Alstonia scholaris (Saptaparna) 5%, Curcuma longa (Haridra) 4.17%, Cissampelous pareira (Patha) 4.17%, Ocimum sanctum (Tulasi) 3.33%, Tinospora cordifolia (Guduci) 3.33%.
4. The herbal formulation as claimed in claim 1, wherein the composition of the herbal formulation comprises the plant part extract ingredients in the range of 2% to 5% Tinospora cordifolia (Guduci extract), 2% to 5% Glycyrrhiza glabra (Yastimadhu extract), 3% to 10% Phyllanthus fraternus (Bhumiamla extract), 3% to 9% Adhatoda vasica (Vasaka extract), 4% to 12% Andrographis paniculate (Bhunimba extract) and 3% to 10% Withania somnifera (Ashwagandha extract).
5. The herbal formulation as claimed in claim I, wherein the composition of the herbal formulation comprises the plant part extract ingredients in (w / w)% Tinospora cordifolia (Guduci extract) 2.5%, Glycyrrhiza glabra (Yastimadhu extract) 2.5%, Phyllanthus fraternus(Bhumiamla extract) 5%, Adhatoda vasica (Vasaka extract) 4.17%, Andrographis paniculate (Bhunimba extract) 5.83% and Withania somnifera (Ashwagandha extract) 5%.
6. The herbal formulation as claimed in claim 1, further containing optionally at least one component selected from pharmaceutically acceptable carrier, excipient, and preservative.
7. The herbal formulation as claimed in claim 1, wherein the herbal formulation comprises plant parts selected from the group comprising of fruits, stem barks, leaves, roots, stolen, whole plants and rhizomes.
8. The herbal formulation as claimed in claim 1, wherein the formulation can be administered in the form of tablets, capsules, pills, powders, granules, aqueous and non aqueous oral solutions and suspensions, creams, hard candies, lozenges, troches, sprays, salves, suppositories, gels, pastes, ointments, jellies, lotions, injectable solutions, elixirs, syrups, and parenteral solutions that is suitable for direct consumption.
9. The herbal formulation as claimed in claim 6, wherein the excipients added in the formulation are selected from the group of starch, crospovidone, croscarmellose sodium, microcrystalline cellulose powder and silicon dioxide.
10. The herbal formulation as claimed in claim 6, wherein the preservatives added in the formulation are one or more of sodium benzoate and potassium sorbate.
11. A process for preparing a herbal formulation, said method comprising the steps of: a) Collecting one or more plant parts selected from flowers, fruits, leaves, seeds, roots, kernels or whole plant, wherein the plant parts are selected from Withania somnifera (Ashwagandha), Aegle marmelos (Bilwa), Glycyrrhiza glabra (Yastimadhu), Pluchea lanceolata (Rasna), Adhatoda vasica (Vasaka), Piper longum (Pippali), Phyllanthus fraternus (Bhumiamla), Andrographis paniculate (Bhunimba), Alstonia scholaris (Saptaparna), Curcuma longa (Haridra), Cissampelous pareira (Patha), Ocimum sanctum (Tulasi) and Tinospora cordifolia (Guduci); b) washing the plant parts obtained in step a) to remove unwanted contaminants and drying the same at room temperature; c) grinding the following dried herbal plant material of step (a) to obtain fine powder: i. Withania somnifera (Ashwagandha) 5%, ii. Aegle marmelos (Bilwa) 5%, iii. Glycyrrhiza glabra (Yastimadhu) 3.33%, iv. Pluchea lanceolata (Rasna) 5%, v. Adhatoda vasica (Vasaka) 4.17%, vi. Piper longum (Pippali) 5%, vii. Phyllanthus fraternus (Bhumiamla) 5.83%, viii. Andrographis paniculate (Bhunimba) 5%, ix. Alstonia scholaris (Saptaparna) 5%, x. Curcuma longa (Haridra) 4.17%, xi. Cissampelous pareira (Patha) 4.17%, xii. Ocimum sanctum (Tulasi) 3.33%, and xiii. Tinospora cordifolia (Guduci) 3.33%, d) preparing the aqueous extracts from the following plants: i. Tinospora cordifolia (Guduci extract) 2.5%, ii. Glycyrrhiza glabra (Yastimadhu extract) 2.5%, iii. Phyllanthus fraternus (Bhumiamla extract) 5%, iv. Adhatoda vasica (Vasaka extract) 4.17%, v. Andrographis paniculate (Bhunimba extract) 5.83% and vi. Withania somnifera (Ashwagandha extract) 5%. e) mixing the fine powders and aqueous extracts of active agents, f) uniformly compressing the active agents along with the excipients and preservatives to prepare tablets.
